Health Care·Biotechnology·$8.0B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.70 | N/A | +4.94% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $1.70 | N/A | +4.94% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management expressed satisfaction with the EPS results, highlighting their commitment to innovation. They did not provide specific guidance for future quarters.
We are pleased with our EPS performance this quarter.
Our focus remains on delivering innovative solutions to our patients.
Krystal Biotech's earnings report shows a positive surprise in EPS, which contributed to a 4.12% increase in stock price. The management's optimistic tone suggests confidence in their ongoing projects, even without specific revenue figures or future guidance. Investors may view the EPS beat as a sign of strong performance amidst uncertainty.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
PALO ALTO NETWORKS I
Feb 17, 2026